Montis' mission is to therapeutically exploit cellular interactions between perivascular macrophages and tumor vasculature to drive and sustain immune reactions against solid tumors.Montis was founded based on the foundational science from the laboratories of Prof. Peter Carmeliet and Massimiliano Mazzone (VIB-KU Leuven), and is backed by an international syndicate of investors.